NewAmsterdam Pharma (NASDAQ:NAMS) Receives $36.20 Consensus Price Target from Analysts

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) have received an average rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $38.17.

A number of research analysts recently commented on NAMS shares. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. HC Wainwright assumed coverage on NewAmsterdam Pharma in a report on Monday. They set a “buy” rating and a $48.00 price target for the company. Scotiabank upped their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd.

NewAmsterdam Pharma Trading Down 1.0 %

NASDAQ:NAMS opened at $25.60 on Thursday. The firm’s fifty day moving average price is $21.99 and its two-hundred day moving average price is $19.17. NewAmsterdam Pharma has a one year low of $11.18 and a one year high of $27.29.

Insider Buying and Selling

In related news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the sale, the insider now owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 416,884 shares of company stock worth $10,676,428. Company insiders own 19.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after purchasing an additional 14,280 shares during the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares in the last quarter. Geode Capital Management LLC boosted its stake in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares in the last quarter. M&T Bank Corp grew its position in NewAmsterdam Pharma by 54.1% in the third quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock valued at $454,000 after acquiring an additional 9,593 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after acquiring an additional 628,251 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.